Bioavailability being address by Capsugel, as well and BASF and Bend Research

Given the industry-wide challenge: how to address issues related to compounds with poor bioavailability, low dosing levels, API potency and stability, so that products can quickly move from development to the marketplace, responding to these customer challenges, Capsugel has announced the creation of its new Dosage Form Solutions(DFS) business unit.

The DFS business unit will focus on the company's growing expertise in lipid-based formulations, while continuing to expand its offerings in targeted release capsules. Capsugel was acquired by Kohlberg Kravis Roberts from Pfizer in 2011 for $2.38 billion.

"With the launch of the new DFS business unit, Capsugel builds on its heritage of delivering innovative, quality products and services in hard capsules, by advancing our expertise in product formulation and commercial finished product manufacturing," said Guido Driesen, president and chief executive of Capsugel, adding: "DFS is well-positioned to help address our customers' most pressing dosage form challenges of existing and new nutritional and pharmaceutical products."